Strongbridge Biopharma: Commercial stage company focused on rare diseases. Topline placebo-controlled Ph3 LOGICS data expected Q3 for RECORLEV™, cortisol synthesis inhibitor for endogenous Cushing's syndrome. Enrollment completion announced May 11, 2020. KEVEYIS® is first and only approved drug for Primary Periodic Paralysis (PPP); Q1'20 revenue up 54% from Q1'19 and guiding to FY20 revenue of $22M-$26M.
Based in...
US - Middle Atlantic
Clinical Stage
Disease Space
Central Nervous System, Rare Disease
Public, USA
Market Cap
100MM - 500MM
900 Northbrook Dr #200
Feasterville Trevose, PA 19053
United States

Company Participants at 2nd Solebury Trout Virtual Global Healthcare Conference Series

John Johnson
Strongbridge Biopharma, Chairman & Interim CEO
John has served as chairman of our board of directors since March 2015. He is a recognized leader in the biopharmaceutical industry with more than 30 years of experience at leading global organizations, including Johnson & Johnson, Eli Lilly & Company, ImClone, and Pfizer, Inc. He currently serves as executive chairman of VirMedica, lead independent director of Sucampo Pharmaceuticals, Inc., and as a member of the board of directors of Cempra Pharmaceuticals, Inc., Histogenics Corporation, and Portola Pharmaceuticals, Inc. John previously served on the board of directors of Pharmaceutical Research and Manufacturers of America (PhRMA), the Health Section Governing Board of Biotechnology Industry Organizations (BIO), and BioNJ.

Top 10 Holders of Strongbridge Biopharma plc

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Caxton Corp. 14.88 8,060,682 17.09 Stakes 9/18/20
NEA Management Co. 7.64 4,141,308 8.78 13F 6/30/20
Ikarian Capital LLC 6.04 3,271,238 6.94 13F 6/30/20
The Vanguard Group, Inc. 3.37 1,824,054 3.87 Funds 8/31/20
Vanguard Group, Inc. (Subfiler) 3.30 1,785,952 3.79 13F 6/30/20
Morgan Stanley Smith Barney LLC 2.47 1,339,172 2.84 13F 6/30/20
Renaissance Technologies LLC 2.32 1,254,600 2.66 13F 6/30/20
BlackRock Fund Advisors 2.30 1,248,232 2.65 13F 6/30/20
Hudson Bay Capital Management LP 2.24 1,213,139 2.57 13F 6/30/20
State Street Corp. 1.36 737,303 1.56 13F 6/30/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.